ASLN
ASLAN Pharmaceuticals Limited
Set alert
52-week range unavailable
- Open
- 0.63
- Prev close
- 0.60
- Mkt cap
- 1.70M
- Vol
- 769.82K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.60
- High
- 0.6999
- Forward P/E
- -0.03
- Beta
- 1.40
- Short ratio
- 1.85
- Inst. own
- 13.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.07
- 200-d avg
- 3.48
- 1y target
- 72.00
Key statistics
- Market cap
- 1.70M
- Enterprise value
- 288.33M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 0.14
- Price / book
- 0.00
- EPS (TTM)
- -16.00
- Beta
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -291.89%
- Revenue (TTM)
- 12.00M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 18.40M
- Total debt
- 26.67M
- Return on equity
- 0.00%
- Shares outstanding
- 2.83M
- Short % of float
- 1.46%
- 50-day average
- 1.07
- 200-day average
- 3.48
Analyst view
Consensus: buy
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -3.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -5.44 | — | — | — |
| Apr 12, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 27, 2023 | Sep 1, 2023 | -6.80 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -6.96 | — | — | — |
| Apr 28, 2023 | Mar 1, 2023 | -6.40 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2023 | Roth MKM | reit | Buy | Buy |
| Jul 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 22, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2023 | Roth MKM | init | — | Buy |
About ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- Website
- aslanpharma.com
News
- Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
- Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
- Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
- ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
- Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
- All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
- Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
- ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
Your note
Sign in to keep a note on ASLN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vivo Capital, LLC | 37.39% | 2,840,908 | 10.37M | Jun 29, 2023 |
| Tang Capital Management, LLC | 14.85% | 1,128,068 | 4.12M | Jun 29, 2023 |
| BVF Inc. | 13.82% | 1,049,999 | 3.83M | Jun 29, 2023 |
| Parkman Healthcare Partners LLC | 6.67% | 506,621 | 1.85M | Jun 29, 2023 |
| Temasek Holdings (Private) Limited | 4.42% | 335,615 | 1.22M | Jun 29, 2023 |
| Sio Capital Management, LLC | 3.34% | 254,150 | 927.65K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Emerging Markets ETF | 0.13% | 9,908 | 21.05K | Aug 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 7,968 | 31.87K | May 30, 2023 |